Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance

Hisashi Urushihara, Nobutaka Kikuchi, Mayumi Yamada, Fumito Yoshiki, Akimitsu Miyauchi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The aim of this study was to assess whether the risks of stroke and stroke death in Japanese postmenopausal women with osteoporosis exposed to raloxifene increased in comparison with those of the general Japanese female population. Methods: Safety data associated with use of raloxifene were collected in observational settings from 6,970 women with a median follow-up period of 366 days on postmarketing surveillance conducted in Japan. The stroke incidences in raloxifene-treated women were compared with population stroke rates derived from epidemiology studies conducted at three distinct locations in Japan, yielding standardized morbidity ratios for stroke for the purpose of stroke risk assessment. Results: Exposure to raloxifene totaled 7,474 patient-years and 23 stroke cases were reported, including 4 fatal cases. Multiple stroke risk factors were present in three of four women with fatal outcome. The standardized stroke morbidity ratios in raloxifene-treated women versus women from the three reference regions, including Akita Prefecture, Takashima town in Shiga Prefecture, and Okinawa Prefecture, were 0.68 (95% CI, 0.45-1.02), 0.54 (95% CI, 0.35-0.83), and 0.82 (95% CI, 0.54-1.24), respectively. Conclusions: In this initial interim analysis, there seems to be no significant increased risk of stroke among Japanese women with 1 year of raloxifene use in comparison to Japanese epidemiological data. An increased risk of fatal stroke in the treatment population was indeterminable because of the small number of observed fatal cases. However, ongoing safety monitoring of stroke risk among raloxifene women will continue.

Original languageEnglish
Pages (from-to)971-977
Number of pages7
JournalMenopause
Volume16
Issue number5
DOIs
Publication statusPublished - 2009 Sep
Externally publishedYes

Fingerprint

Osteoporosis
Stroke
Raloxifene Hydrochloride
Japan
Population
Morbidity
Safety
Fatal Outcome
Epidemiology
Incidence

Keywords

  • Japanese women
  • Postmarketing surveillance
  • Postmenopausal osteoporosis
  • Raloxifene
  • Stroke risk

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance. / Urushihara, Hisashi; Kikuchi, Nobutaka; Yamada, Mayumi; Yoshiki, Fumito; Miyauchi, Akimitsu.

In: Menopause, Vol. 16, No. 5, 09.2009, p. 971-977.

Research output: Contribution to journalArticle

Urushihara, Hisashi ; Kikuchi, Nobutaka ; Yamada, Mayumi ; Yoshiki, Fumito ; Miyauchi, Akimitsu. / Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance. In: Menopause. 2009 ; Vol. 16, No. 5. pp. 971-977.
@article{6827713b8c1441918417b2be14ded98c,
title = "Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance",
abstract = "Objective: The aim of this study was to assess whether the risks of stroke and stroke death in Japanese postmenopausal women with osteoporosis exposed to raloxifene increased in comparison with those of the general Japanese female population. Methods: Safety data associated with use of raloxifene were collected in observational settings from 6,970 women with a median follow-up period of 366 days on postmarketing surveillance conducted in Japan. The stroke incidences in raloxifene-treated women were compared with population stroke rates derived from epidemiology studies conducted at three distinct locations in Japan, yielding standardized morbidity ratios for stroke for the purpose of stroke risk assessment. Results: Exposure to raloxifene totaled 7,474 patient-years and 23 stroke cases were reported, including 4 fatal cases. Multiple stroke risk factors were present in three of four women with fatal outcome. The standardized stroke morbidity ratios in raloxifene-treated women versus women from the three reference regions, including Akita Prefecture, Takashima town in Shiga Prefecture, and Okinawa Prefecture, were 0.68 (95{\%} CI, 0.45-1.02), 0.54 (95{\%} CI, 0.35-0.83), and 0.82 (95{\%} CI, 0.54-1.24), respectively. Conclusions: In this initial interim analysis, there seems to be no significant increased risk of stroke among Japanese women with 1 year of raloxifene use in comparison to Japanese epidemiological data. An increased risk of fatal stroke in the treatment population was indeterminable because of the small number of observed fatal cases. However, ongoing safety monitoring of stroke risk among raloxifene women will continue.",
keywords = "Japanese women, Postmarketing surveillance, Postmenopausal osteoporosis, Raloxifene, Stroke risk",
author = "Hisashi Urushihara and Nobutaka Kikuchi and Mayumi Yamada and Fumito Yoshiki and Akimitsu Miyauchi",
year = "2009",
month = "9",
doi = "10.1097/gme.0b013e3181a15622",
language = "English",
volume = "16",
pages = "971--977",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance

AU - Urushihara, Hisashi

AU - Kikuchi, Nobutaka

AU - Yamada, Mayumi

AU - Yoshiki, Fumito

AU - Miyauchi, Akimitsu

PY - 2009/9

Y1 - 2009/9

N2 - Objective: The aim of this study was to assess whether the risks of stroke and stroke death in Japanese postmenopausal women with osteoporosis exposed to raloxifene increased in comparison with those of the general Japanese female population. Methods: Safety data associated with use of raloxifene were collected in observational settings from 6,970 women with a median follow-up period of 366 days on postmarketing surveillance conducted in Japan. The stroke incidences in raloxifene-treated women were compared with population stroke rates derived from epidemiology studies conducted at three distinct locations in Japan, yielding standardized morbidity ratios for stroke for the purpose of stroke risk assessment. Results: Exposure to raloxifene totaled 7,474 patient-years and 23 stroke cases were reported, including 4 fatal cases. Multiple stroke risk factors were present in three of four women with fatal outcome. The standardized stroke morbidity ratios in raloxifene-treated women versus women from the three reference regions, including Akita Prefecture, Takashima town in Shiga Prefecture, and Okinawa Prefecture, were 0.68 (95% CI, 0.45-1.02), 0.54 (95% CI, 0.35-0.83), and 0.82 (95% CI, 0.54-1.24), respectively. Conclusions: In this initial interim analysis, there seems to be no significant increased risk of stroke among Japanese women with 1 year of raloxifene use in comparison to Japanese epidemiological data. An increased risk of fatal stroke in the treatment population was indeterminable because of the small number of observed fatal cases. However, ongoing safety monitoring of stroke risk among raloxifene women will continue.

AB - Objective: The aim of this study was to assess whether the risks of stroke and stroke death in Japanese postmenopausal women with osteoporosis exposed to raloxifene increased in comparison with those of the general Japanese female population. Methods: Safety data associated with use of raloxifene were collected in observational settings from 6,970 women with a median follow-up period of 366 days on postmarketing surveillance conducted in Japan. The stroke incidences in raloxifene-treated women were compared with population stroke rates derived from epidemiology studies conducted at three distinct locations in Japan, yielding standardized morbidity ratios for stroke for the purpose of stroke risk assessment. Results: Exposure to raloxifene totaled 7,474 patient-years and 23 stroke cases were reported, including 4 fatal cases. Multiple stroke risk factors were present in three of four women with fatal outcome. The standardized stroke morbidity ratios in raloxifene-treated women versus women from the three reference regions, including Akita Prefecture, Takashima town in Shiga Prefecture, and Okinawa Prefecture, were 0.68 (95% CI, 0.45-1.02), 0.54 (95% CI, 0.35-0.83), and 0.82 (95% CI, 0.54-1.24), respectively. Conclusions: In this initial interim analysis, there seems to be no significant increased risk of stroke among Japanese women with 1 year of raloxifene use in comparison to Japanese epidemiological data. An increased risk of fatal stroke in the treatment population was indeterminable because of the small number of observed fatal cases. However, ongoing safety monitoring of stroke risk among raloxifene women will continue.

KW - Japanese women

KW - Postmarketing surveillance

KW - Postmenopausal osteoporosis

KW - Raloxifene

KW - Stroke risk

UR - http://www.scopus.com/inward/record.url?scp=73349089010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349089010&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e3181a15622

DO - 10.1097/gme.0b013e3181a15622

M3 - Article

VL - 16

SP - 971

EP - 977

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 5

ER -